RGBP
Regen BioPharma, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+100.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 4,964,669 |
Stock Information
| Shares Outstanding | 511.96M |
| Total Debt | $959K |
| Cash Equivalents | $271 |
| Revenue | $237K |
| Net Income | $-716K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $102K |
| EPS (TTM) | $-0.02 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.05M |
| Sales | $237K |
| Income | $-716K |
| Book/sh | $-0.01 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.05 |
| Current Ratio | 0.05 |
Returns & Margins
| ROA | -252.85% |
| Gross Margin | 100.00% |
| Operating Margin | -260.24% |
Ownership
| Insider Ownership | 9.92% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.43 |
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.01 |
| RSI | 39.47 |
| ATR | 0.0001 |
| Shares Float | 465.70M |
| Volatility | 0.19 |
| Rel Volume | 0.34 |
Performance History
| Week | +100.00% |
| Month | -50.00% |
| Quarter | -73.33% |
| 6 Months | -97.18% |
| YTD | -97.72% |
| Year | -99.64% |
| 3 Years | -99.98% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $0.00 | 10,101,360 |
| 2026-06-15 | $0.00 | 5,785,054 |
| 2026-06-12 | $0.00 | 524,252 |
| 2026-06-11 | $0.00 | 1,968,566 |
| 2026-06-10 | $0.00 | 8,853,037 |
| 2026-06-09 | $0.00 | 114,280,078 |
| 2026-06-08 | $0.00 | 123,404,411 |
| 2026-06-05 | $0.00 | 51,416,335 |
| 2026-06-04 | $0.00 | 15,071,032 |
| 2026-06-03 | $0.00 | 5,582,993 |
| 2026-06-02 | $0.00 | 3,099,077 |
| 2026-06-01 | $0.00 | 34,952,613 |
| 2026-05-29 | $0.00 | 31,900,198 |
| 2026-05-28 | $0.00 | 29,412,295 |
| 2026-05-27 | $0.00 | 49,500,683 |
| 2026-05-26 | $0.00 | 15,804,462 |
| 2026-05-22 | $0.00 | 21,729,937 |
| 2026-05-21 | $0.00 | 20,770,420 |
| 2026-05-20 | $0.00 | 40,759,013 |
| 2026-05-19 | $0.00 | 1,152,200 |
| 2026-05-18 | $0.00 | 3,630,156 |
About Regen BioPharma, Inc.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on RGBP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $236,561 | $236,560 | $236,560 | $235,517 |
| Operating Revenue | $236,561 | $236,560 | $236,560 | $235,517 |
| Expenses | ||||
| Interest Expense | $210,434 | $101,443 | $59,448 | $209,787 |
| Total Expenses | $575,101 | $653,781 | $923,509 | $575,122 |
| Rent Expense Supplemental | $90,000 | $77,215 | $60,000 | $50,000 |
| Other Income Expense | $-725,528 | $-4,091 | $2,152,905 | $3,037,969 |
| Other Non Operating Income Expenses | $-50,000 | - | - | $-237,300 |
| Net Non Operating Interest Income Expense | $-210,434 | $-246,943 | $-309,448 | $-254,832 |
| Interest Expense Non Operating | $210,434 | $101,443 | $59,448 | $209,787 |
| Operating Expense | $575,101 | $653,781 | $923,509 | $575,122 |
| General And Administrative Expense | $563,376 | $500,096 | $711,212 | $299,734 |
| Total Other Finance Cost | - | $145,500 | $250,000 | $45,500 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,274,502 | $-668,255 | $1,023,508 | $2,227,034 |
| Net Interest Income | $-210,434 | $-246,943 | $-309,448 | $-254,832 |
| Normalized Income | $-598,974 | $-664,164 | $-1,129,397 | $-360,429 |
| Net Income From Continuing And Discontinued Operation | $-1,274,502 | $-668,255 | $1,023,508 | $2,227,034 |
| Total Operating Income As Reported | $-338,540 | $-417,221 | $-686,950 | $-339,605 |
| Net Income Common Stockholders | $-1,274,502 | $-668,255 | $1,023,508 | $2,227,034 |
| Net Income | $-1,274,502 | $-668,255 | $1,023,508 | $2,227,034 |
| Net Income Including Noncontrolling Interests | $-1,274,502 | $-668,255 | $1,156,507 | $2,443,531 |
| Net Income Continuous Operations | $-1,274,502 | $-668,255 | $1,156,508 | $2,443,532 |
| Pretax Income | $-1,274,502 | $-668,255 | $1,156,508 | $2,443,532 |
| Operating Income | $-338,540 | $-417,221 | $-686,949 | $-339,605 |
| Special Income Charges | - | $0 | $1,150 | $-95,019 |
| Interest Income | - | - | $0 | $455 |
| Interest Income Non Operating | - | - | $0 | $455 |
| Per Share | ||||
| Diluted EPS | - | $-0.06 | $0.14 | $0.36 |
| Basic EPS | - | $-0.06 | $0.14 | $0.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $687,806 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-388,540 | $-562,721 | $-936,949 | $-621,950 |
| Total Unusual Items | $-675,528 | $-4,091 | $2,152,905 | $3,275,269 |
| Total Unusual Items Excluding Goodwill | $-675,528 | $-4,091 | $2,152,905 | $3,275,269 |
| EBITDA (Bullshit earnings) | $-1,064,068 | $-566,812 | $1,215,956 | $2,653,319 |
| EBIT | $-1,064,068 | $-566,812 | $1,215,956 | $2,653,319 |
| Diluted NI Availto Com Stockholders | $-1,274,502 | $-668,255 | $1,023,508 | $2,227,034 |
| Tax Provision | $0 | $0 | $0 | - |
| Gain On Sale Of Security | $-675,528 | $-4,091 | $2,151,755 | $3,370,288 |
| Research And Development | $11,725 | $153,685 | $212,297 | $275,388 |
| Selling General And Administration | $563,376 | $500,096 | $711,212 | $299,734 |
| Other Gand A | $473,376 | $422,881 | $651,212 | $249,734 |
| Rent And Landing Fees | $90,000 | $77,215 | $60,000 | $50,000 |
| Diluted Average Shares | - | $10,516,470 | $7,073,926 | $6,271,692 |
| Basic Average Shares | - | $10,516,470 | $7,073,926 | $6,271,692 |
| Other Special Charges | - | - | $-1,150 | $95,019 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,281,183 | $-5,217,372 | $-5,103,999 | $-8,036,059 |
| Total Assets | $274,628 | $161,084 | $353,617 | $559,002 |
| Total Non Current Assets | $0 | $17,733 | $222,580 | $222,580 |
| Investmentin Financial Assets | $0 | $17,733 | $222,579 | $222,580 |
| Current Assets | $274,628 | $143,351 | $131,037 | $336,422 |
| Prepaid Assets | $200 | $47,762 | $10,000 | $30,945 |
| Receivables | $204,873 | $94,873 | $0 | $254,273 |
| Accounts Receivable | $204,873 | $94,873 | $0 | $254,273 |
| Cash Cash Equivalents And Short Term Investments | $69,555 | $716 | $121,037 | $51,204 |
| Cash And Cash Equivalents | $69,555 | $716 | $121,037 | $51,204 |
| Cash Financial | $69,555 | $716 | $121,037 | $51,204 |
| Other Non Current Assets | - | - | $1 | - |
| Notes Receivable | - | - | $0 | $0 |
| Accrued Interest Receivable | - | - | - | $0 |
| Debt | ||||
| Net Debt | $1,128,305 | $792,983 | $634,167 | $1,222,846 |
| Total Debt | $1,197,860 | $793,699 | $755,204 | $1,274,050 |
| Current Debt And Capital Lease Obligation | $1,197,860 | $793,699 | $605,590 | $1,274,050 |
| Current Debt | $1,197,860 | $793,699 | $605,590 | $1,274,050 |
| Other Current Borrowings | $1,006,521 | $499,880 | $605,590 | $1,273,050 |
| Long Term Debt And Capital Lease Obligation | - | - | $149,614 | - |
| Long Term Debt | - | - | $149,614 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,555,811 | $5,378,456 | $5,457,616 | $8,595,061 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $149,614 | $0 |
| Current Liabilities | $6,555,811 | $5,378,456 | $5,308,002 | $8,595,061 |
| Other Current Liabilities | $2,179,386 | $1,425,090 | $1,421,000 | $3,551,794 |
| Current Deferred Liabilities | $1,338,611 | $1,465,171 | $1,606,857 | $1,718,290 |
| Current Notes Payable | $191,339 | $293,819 | - | $710 |
| Payables And Accrued Expenses | $1,839,954 | $1,694,496 | $1,674,555 | $2,050,927 |
| Interest Payable | $476,434 | $362,533 | $342,588 | $689,785 |
| Payables | $30,467 | $33,910 | $33,914 | $53,040 |
| Total Tax Payable | $28,753 | $4,241 | $4,241 | $4,241 |
| Accounts Payable | $1,714 | $29,669 | $29,673 | $28,799 |
| Other Non Current Liabilities | - | $1 | $-1 | - |
| Other Payable | - | - | $20,000 | $20,000 |
| Equity | ||||
| Common Stock Equity | $-6,282,199 | $-5,218,388 | $-5,104,044 | $-8,084,394 |
| Preferred Stock Equity | $1,016 | $1,016 | $45 | $48,335 |
| Total Equity Gross Minority Interest | $-6,281,183 | $-5,217,372 | $-5,103,999 | $-8,036,059 |
| Stockholders Equity | $-6,281,183 | $-5,217,372 | $-5,103,999 | $-8,036,059 |
| Gains Losses Not Affecting Retained Earnings | $-222,580 | $-204,847 | - | - |
| Other Equity Adjustments | $-222,580 | $-204,847 | - | - |
| Retained Earnings | $-21,691,620 | $-20,417,118 | $-19,748,863 | $-20,905,369 |
| Other | ||||
| Preferred Shares Number | $10,123,771 | $10,123,771 | $1,228,653 | $878,586 |
| Ordinary Shares Number | $39,374,704 | $10,516,470 | $7,012,732 | $6,708,690 |
| Share Issued | $39,374,704 | $10,516,470 | $7,012,732 | $6,708,690 |
| Tangible Book Value | $-6,282,199 | $-5,218,388 | $-5,104,044 | $-8,084,394 |
| Invested Capital | $-5,084,339 | $-4,424,689 | $-4,348,840 | $-6,810,344 |
| Working Capital | $-6,281,183 | $-5,235,105 | $-5,176,965 | $-8,258,639 |
| Total Capitalization | $-6,281,183 | $-5,217,372 | $-4,954,385 | $-8,036,059 |
| Additional Paid In Capital | $15,628,062 | $15,403,050 | $14,644,467 | $12,317,825 |
| Capital Stock | $4,955 | $1,543 | $397 | $551,485 |
| Common Stock | $3,939 | $527 | $352 | $503,150 |
| Preferred Stock | $1,016 | $1,016 | $45 | $48,335 |
| Current Deferred Revenue | $1,338,611 | $1,465,171 | $1,606,857 | $1,718,290 |
| Current Accrued Expenses | $1,809,487 | $1,660,586 | $1,640,641 | $1,997,887 |
| Investments And Advances | $0 | $17,733 | $222,579 | $222,580 |
| Available For Sale Securities | - | $17,733 | $222,579 | $222,580 |
| Duefrom Related Parties Current | - | $94,873 | $0 | $254,273 |
| Line Of Credit | - | - | $1,000 | $1,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-383,591 | $-751,536 | $-173,917 | $-606,921 |
| Operating Activities | ||||
| Operating Cash Flow | $-383,591 | $-751,536 | $-173,917 | $-606,921 |
| Cash Flow From Continuing Operating Activities | $-383,591 | $-751,536 | $-173,917 | $-606,922 |
| Operating Gains Losses | $675,528 | $4,090 | $-2,151,755 | $1,828 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | - | $25,000 |
| Cash Flow From Continuing Investing Activities | - | - | - | $25,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $58,200 | $563,722 | $0 | - |
| Financing Cash Flow | $452,430 | $631,215 | $243,750 | $-94,036 |
| Cash Flow From Continuing Financing Activities | $452,430 | $631,215 | $243,750 | $-94,036 |
| Net Other Financing Charges | $50,000 | - | - | - |
| Net Common Stock Issuance | $58,200 | $563,722 | $0 | - |
| Common Stock Issuance | $58,200 | $563,722 | $0 | - |
| Other | ||||
| Issuance Of Debt | $344,230 | $77,493 | $243,750 | $499 |
| End Cash Position | $69,555 | $716 | $121,037 | $51,204 |
| Beginning Cash Position | $716 | $121,037 | $51,204 | $727,162 |
| Changes In Cash | $68,839 | $-120,321 | $69,833 | $-675,958 |
| Net Issuance Payments Of Debt | $344,230 | $67,493 | $243,750 | $-94,036 |
| Net Short Term Debt Issuance | $344,230 | $67,493 | $243,750 | $-94,036 |
| Short Term Debt Issuance | $344,230 | $77,493 | $243,750 | $499 |
| Change In Working Capital | $35,135 | $-254,384 | $223,245 | $-3,137,415 |
| Change In Other Working Capital | $-126,560 | $-141,687 | $-111,433 | $-125,517 |
| Change In Other Current Liabilities | $50,000 | $0 | $-2,151,755 | $-3,040,683 |
| Change In Payables And Accrued Expense | $174,133 | $19,939 | $59,459 | $47,042 |
| Change In Accrued Expense | $173,312 | $19,946 | $58,583 | $109,747 |
| Change In Payable | $821 | $-7 | $876 | $-62,705 |
| Change In Account Payable | $821 | $-7 | $876 | $-62,705 |
| Change In Prepaid Assets | $47,562 | $-37,762 | $20,947 | $17,199 |
| Change In Receivables | $-110,000 | $-94,874 | $254,272 | $-35,456 |
| Changes In Account Receivables | $-110,000 | $-94,874 | $254,272 | $-41,082 |
| Other Non Cash Items | $180,248 | $116,502 | $249,714 | $116,568 |
| Gain Loss On Investment Securities | $675,528 | $4,090 | $-2,151,755 | $1,828 |
| Net Income From Continuing Operations | $-1,274,502 | $-668,255 | $1,156,507 | $2,443,531 |
| Repayment Of Debt | - | $-10,000 | $0 | $-94,535 |
| Short Term Debt Payments | - | $-10,000 | $0 | $-94,535 |
| Stock Based Compensation | - | $50,511 | $348,372 | $0 |
| Interest Paid Supplemental Data | - | - | - | $27,473 |
| Net Long Term Debt Issuance | - | - | - | $-94,535 |
| Net Investment Purchase And Sale | - | - | - | $25,000 |
| Sale Of Investment | - | - | - | $25,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $-31,433 |
Fetched: 2026-02-02